Stocks · News reference
8-K filing — Janux Therapeutics, Inc. (JANX)
Filed: 2026-06-23 AccNo: 0001193125-26-279428 Size: 155 KB Item 8.01: Other Events
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.